Bioretec (BRETEC) Q3 2025 earnings summary

Executive summary

• Net sales for Q3 2025 were EUR 715 thousand, up 4.5% year-over-year; for January–September, net sales reached EUR 2,789 thousand, a 1.6% increase year-over-year.

• The company is undergoing a strategic transition, with new CEO and CFO appointments and a focus on strengthening commercial leadership and strategy.

• Previous financial targets have been withdrawn due to longer FDA approval timelines, financing needs, and strategic adjustments.

Financial highlights

• Q3 2025 EBITDA was EUR -1,768 thousand, compared to EUR -1,353 thousand in Q3 2024; January–September EBITDA was EUR -6,325 thousand, down from EUR -3,217 thousand year-over-year.

• Q3 2025 net loss was EUR -1,854 thousand, compared to EUR -1,367 thousand in Q3 2024; January–September net loss was EUR -7,482 thousand, compared to EUR -3,251 thousand year-over-year.

• Cash and cash equivalents at period end were EUR 7,263 thousand, up 205.5% year-over-year.

Outlook and guidance

• Revised commercialization strategy and financial targets will be provided by the end of 2025.

• No accelerated sales expected in 2025; previous targets for net sales and positive cash flow have been withdrawn.